Singh Shawn
SEC insider (Form 3/4/5 filer). CIK 0001412071. President and CEO at Vistagen Therapeutics, Inc. (VTGN). 5 reported Form 4/5 transactions since Sep 2024; latest on Jun 30, 2026. Located in SOUTH SAN FRANCISCO, CA.
Companies Singh Shawn has filed insider reports for
- Vistagen Therapeutics, Inc. (VTGN): Director, Officer, President and CEO
Singh Shawn
CIK: 0001412071
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Vistagen Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Jun 30, 2026VTGN
Vistagen Therapeutics, Inc.
AwardDirect36.8K shares at avg. $0.19$7K - Apr 7, 2026VTGN
Vistagen Therapeutics, Inc.
AwardDirectIncentive Stock Option (right to buy)
3.7K shares- - Apr 7, 2026VTGN
Vistagen Therapeutics, Inc.
AwardDirectNon-Qualified Stock Option (right to buy)
71.3K shares- - Jun 30, 2025VTGN
Vistagen Therapeutics, Inc.
AwardDirect7.5K shares at avg. $1.70$13K - Jun 23, 2025VTGN
Vistagen Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
300K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 30, 2026 | VTGN Vistagen Therapeutics, Inc. | Award | 36,818 | $0.19 | $7,073 | Direct |
| Apr 7, 2026 | VTGN Vistagen Therapeutics, Inc. | Award Incentive Stock Option (right to buy) | 3,732 | - | - | Direct |
| Apr 7, 2026 | VTGN Vistagen Therapeutics, Inc. | Award Non-Qualified Stock Option (right to buy) | 71,268 | - | - | Direct |
| Jun 30, 2025 | VTGN Vistagen Therapeutics, Inc. | Award | 7,541 | $1.70 | $12,820 | Direct |
| Jun 23, 2025 | VTGN Vistagen Therapeutics, Inc. | Award Stock Option (Right to Buy) | 300,000 | - | - | Direct |
1-5 of 5 transactions